Abstract: Objective To evaluate the efficacy and safety of thalidomide plus the third generation platinum-contained chemotherapy regimen for patients with advanced non-small cell lung cancer（NSCLC）. Methods Relevant randomized controlled trials（RCT） were searched from Cochrane library,PubMed,EMBase,CancerLit,VIP,CBM,etc.RCT of thalidomide plus the third generation platinum-contained chemotherapy regimen vs the third generation platinum-contained chemotherapy regimen for advanced NSCLC were included.Quality of these included studies was analyzed using the Cochrane Collaboration’s RevMan 5.0 software. Results Nine RCTs involving 1 256 patients were included.Meta analysis showed no significant difference in effective rate,clinical benefit rate,bone marrow inhibition,digestive tract reaction,renal and neural system toxicity between the two treatment modalities.The serum VEGF level（RR=-91.43,95%CI=125.82 and 57.03,P＜0.000 01） was significantly lower and the incidence of thrombotic events（RR=1.74,95% CI=1.20-2.52,P=0.003） and rashes（RR=4.23,95%CI: 1.45-12.39,P=0.008） was significantly higher after treatment with thalidomide plus the third generation platinum-contained chemotherapy regimen than with the third generation platinum-contained chemotherapy regimen alone. Conclusion Thalidomide plus the third generation platinum-contained chemotherapy regimen cannot improve the short-term therapeutic effect on NSCLC,but it can decrease the serum VEGF level and increase the incidence of thrombotic events and rashes more significantly than the third generation platinum-contained chemotherapy regimen alone,it is thus not recommended for advanced NSCLC.